TABLE 1.

Demographics and patient characteristics.

	MACE cohort (N = 16 012)		Malignancy cohort (N = 14 545)
	n	%	n	%
Female	10 358	64.69	9730	66.90
Age, years
18–49	1649	10.30	1582	10.88
50–64	3190	19.92	2945	20.25
65–74	4593	28.68	4009	27.56
≥ 75	6580	41.09	6009	41.31
BMI, kg/m2
< 18.5	771	4.82	655	4.50
≤ 18.5–< 25	2771	17.31	2352	16.17
≥ 25	959	5.99	814	5.60
N/A	11 511	71.89	10 724	73.73
Smoking status
Non‐smoker	3181	19.87	2843	19.55
Smoker	1242	7.76	927	6.37
N/A	11 589	72.38	10 775	74.08
Comorbidities
Diabetes	2714	16.95	2378	16.35
Cerebrovascular disease	2492	15.56	2632	18.10
Cardiovascular disease	4331	27.05	4271	29.36
Fracture diagnosis	2436	15.21	2250	15.47
Hypertension	6383	39.86	5741	39.47
Hyperlipidemia	4740	29.60	4305	29.60
Malignancy	4762	29.74	—	—
Renal disease	1388	8.67	1181	8.12
Unspecified chronic bronchitis	1212	7.57	1013	6.96
Emphysema	491	3.07	340	2.34
Other COPD	540	3.37	408	2.81
Serious infection	4015	25.07	3496	24.04
Medications
NSAIDs	9125	56.99	8230	56.58
Glucocorticoids, daily dose, mg
0	6018	37.58	5644	38.80
> 0–< 5	8112	50.66	7316	50.30
≥ 5–< 10	1126	7.03	947	6.51
≥ 10	756	4.72	638	4.39
bDMARDs	900	5.62	867	5.96
csDMARDs	8505	53.12	7941	54.60
Methotrexate, weekly dose, mg
0	11 733	73.28	10 472	72.00
> 0–≤ 8	3730	23.30	3554	24.43
> 8	549	3.43	519	3.57
JAK inhibitor	49	0.31	48	0.33
Calcineurin inhibitor	1086	6.78	1002	6.89
Past history
Deep vein thrombosis	260	1.62	218	1.50
MACE	67	0.42	82	0.56
Malignancy	4731	29.55	3362	23.11
Pulmonary embolism	34	0.21	25	0.17
Prior X‐ray examination	11 100	69.32	9855	67.76

Abbreviations: bDMARD, biologic disease‐modifying antirheumatic drug; BMI, body mass index; COPD, chronic obstructive pulmonary disease; csDMARD, conventional synthetic disease‐modifying antirheumatic drug; JAK, Janus kinase; MACE, major adverse cardiovascular events; N, total number of eligible patients; n, number of patients with characteristic; N/A, not available; NSAID, nonsteroidal anti‐inflammatory drug.